contract and agreement category list home search signinup contracts dictionary clauses companies people about faq blog sample contract categories a b c d e f g h i j k l m n o p q r s t u v w x y z abcdefghijklmnopqrstuvwxyz k delaware k new york k california k texas k agreement k nevada k florida k maryland k illinois k employment agreement k washington k amended and restated k massachusetts k new jersey k pennsylvania k georgia k colorado k ohio k minnesota k virginia k north carolina k incentive plan k credit agreement k amendment k connecticut k michigan k indiana k registration rights agreement k recitals k tennessee k arizona k missouri k purchase agreement k promissory note k indenture k warrant k louisiana k kansas k utah k wisconsin k oklahoma k securities purchase agreement k agreement and plan of merger k iowa k supplemental indenture k note k equity incentive plan k kentucky k stock purchase agreement k alabama × have an account sign in here law insider recover your password no account register now no account register now sign in by using one of this services or forgot your password have an account sign in here join law insider for free by using one of this services or by registering you agree to our terms of service asset purchase clause agreement library  you are here contract clause  asset purchase agreement clauses search documents  browse documents site search agreements  contracts document title entire documentoptional governing lawoptional allalabamaalaskaarizonaarkansascaliforniacoloradoconnecticutdelawareflorida georgiahawaiiidahoillinoisindianaiowakansaskentuckylouisianamainemaryland massachusettsmichiganminnesotamississippimissourimontananebraskanevada new hampshirenew jerseynew mexiconew yorknorth carolinanorth dakotaohiooklahoma oregonpennsylvaniarhode islandsouth carolinasouth dakotatennesseetexasutah vermontvirginiawashingtonwest virginiawisconsinwyoming try our advanced search  clauses search contract clauses  browse contract clause library asset purchase clause library find the right asset purchase clause for your asset purchase contract our asset clause library contains thousands of clauses from actual purchase agreements drafted by top law firms access to the entire sample clause library at realdealdocscom is free and we have several affordable membership options to our legal agreements library browse the list below to find an asset clause such as a liability clause sale and purchase clauses or any other contract provision for an asset purchase contract contract clauses   purchase and sale of assets clauses     retention of records clauses     liabilities assumed clauses     liabilities excluded clauses     closing clauses   consideration clauses     purchase price clauses     purchase price allocation clauses     working capital clauses     earnout clauses     payment of purchase price clauses     payment of taxes clauses   representations and warranties clauses     organization clauses     authority clauses     consents and approvals clauses     noncontravention clauses     intellectual property clauses     litigation clauses     compliance clauses     brokers clauses     noncompetition clauses     financial statements clauses     contracts clauses     undisclosed liabilities clauses     taxes clauses     product liability clauses     product liabilties clauses     product warranty clauses     accounts receivable clauses     receivables clauses     permits clauses     employees clauses     real property clauses     environmental matters clauses     insurance clauses     employee benefits clauses     section a clauses   conditions precedent clauses   termination clauses     effect of termination clauses     termination for cause clauses     termination without cause clauses     material breach clauses     insolvency clauses     bankruptcy clauses   liability clauses     indemnification clauses     indemnity clauses     limitation of liability clauses     damages clauses     claims clauses   alternative dispute resolution clauses     waiver of jury trial clauses     mediation clauses     arbitration clauses   governing law clauses     choice of venue clauses     jurisdiction clauses     choice of law clauses     applicable law clauses   miscellaneous clauses     remedies clauses     integration clauses     notices clauses     entire agreement clauses     severability clauses     survival clauses     force majeure clauses     amendment or waiver clauses     counterparts clauses     headings clauses     construction clauses     relationship of parties clauses     assignment clauses spectrum pharmaceuticals cayman lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors spectrum pharmaceuticals cayman lp check out list of companies and businesses related to spectrum pharmaceuticals cayman lp find out spectrum pharmaceuticals cayman lp address and contact details view other people related to spectrum pharmaceuticals cayman lp  coworkers colleagues companions etc address co spectrum pharmaceuticals inc  s eastern ave ste  henderson  nv companies related to spectrum pharmaceuticals cayman lp cikcompany namepositioncompany addresscasi pharmaceuticals inc medical center dr ste  rockville  spectrum pharmaceuticals cayman lp on the web persons related to spectrum pharmaceuticals cayman lp  casi pharmaceuticals incnamepositioncitykenneth walter bairsvp research and development rockvillethomas h bliss jrsvp bus  corp development rockvillemark r brayvice president research torontodonald s brooksdirector rockvilledonald s brooksdirector rockvillejames s burnspresident and ceo rockvillejames s burnspresident and ceo rockvilledwight l bushdirector rockvilledwight l bushdirector rockvilledwight l bushdirector rockvilledwight l bushdirector rockvilledwight l bushdirector rockvilleneil j campbellpresident and coo rockvilleronald capedirector rockvilleronald capedirector rockvillesara b capitellivp fin  principal account off rockvillesara b capitellivp fin  principal accounting rockvillesara b capitellivp finance  pao rockvillesara b capitellivp finance  pao rockvillesidor carolynrockvillecelgene corp de owner summitmarc corradovp corporate development rockvillemarc corradovp corporate development rockvillehu cynthiarockvillebush dwightrockvilleweiwu hedirector rockvilleweiwu hedirector rockvilleweiwu hedirector rockvilleweiwu hedirector rockvilleweiwu hedirector rockvillehe xie ai qi investment management beijing co ltdbeijingchi sing hocentralcynthia w hucoo general counsel and secy rockvillecynthia w hucoo general counsel  sec rockvillecynthia w husee remarks rockvillecynthia w husee remarks rockvillejames huangdirector rockvillejames huangdirector rockvillejames huangdirector rockvillejames huangdirector rockvillecevera jennie hunterdirector rockvillecevera jennie hunterdirector rockvillecevera jennie hunterdirector rockvillecevera jennie hunterdirector rockvillecevera jennie hunterdirector rockvilleidgaccel china growth fund gp iii associates ltdkidgaccel china growth fund iii associates lpkidgaccel china growth fund iii lp owner kidgaccel china iii investors lpkhuntercevera jennierockvilleudo kleinsenior vice president of rd rockvillepeter s knightdirector rockvillepeter s knightdirector rockvillejianguang libeijingdongliang linbeijingtak w makdirector rockvilletak w makdirector rockvilletak w makdirector rockvilletak w makdirector rockvillebray markrockvillerandall markrockvillemark c m randalldirector rockvillemark c m randalldirector rockvillemark c m randalldirector rockvilleken renceo and director west des moinesken keyong renchief executive officer rockvilleken keyong renchief executive officer rockvilleken keyong renchief executive officer rockvilledane r sagliochief financial officer rockvilledane r sagliochief financial officer rockvillefranklin cary salisbury jrdirector rockvillecapitelli sararockvillehugo shongbeijingrajesh c md shrotriyadirector irvinerajesh c md shrotriyadirector rockvillecarolyn f sidorcorp vp and chief med ofcr rockvillecarolyn f sidorvp and chief medical officer rockvillesnow moon ltdroad townsparkle byte ltd owner road townspectrum pharmaceuticals inc owner hendersonspectrum pharmaceuticals inchendersonmak takrockvillemichael m tarnowdirector rockvillemichael m tarnowdirector rockvillejingran management center limited partnership tianjintianjinkathy wehmeirdavisprincipal accounting officer rockvillehe weiwurockvillecynthia wongcoo gen counsel and secretary rockvillecynthia wongcoo  general counsel rockvillealex wudirector rockvillealex wudirector rockvillealex wudirector rockvillefei yangguangzhousuyang zhangshanghaiquan zhoudirector centralalexander a zukiwskichief medical officer flemington spectrum pharmaceuticals cayman lp private company information  bloomberg july    pm et company overview of spectrum pharmaceuticals cayman lp snapshot people company overview spectrum pharmaceuticals cayman lp operates as a subsidiary of spectrum pharmaceuticals inc  south eastern avenuesuite henderson nv united states key executives for spectrum pharmaceuticals cayman lp spectrum pharmaceuticals cayman lp does not have any key executives recorded similar private companies by industry company name region aryzta us holdings i corp united states michael anthony hernandez a professional corp united states solutions group united states atlantic telesatellite inc united states d construction inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact spectrum pharmaceuticals cayman lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close spectrum pharmaceuticals inc product portfolio  commercial our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensingglossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials expanded access program careers contact us home  product portfolio  commercial marketed products spectrum and its subsidiaries have six fdaapproved oncologyhematology products available through our commercial team of regional oncology specialists for more information on the spectrums marketed products please click on the respective product web site links below indications and usage for fusilev fusilev a folate analog is available commercially in vials for injection as freezedried powder in  spectrum pharmaceuticals sought multiple supply sources for fusilev to offset any demand increase currently spectrum is able to meet all supply requirements fusilev is a folate analog indicated for  rescue after highdose methotrexate therapy in osteosarcoma  diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists  use in combination chemotherapy with fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer limitations of use • fusilev is not approved for pernicious anemia and megaloblastic anemias improper use may cause a hematologic remission while neurologic manifestations continue to progress important safety information for fusilev contraindications  fusilev is contraindicated for patients who have had previous allergic reactions attributed to folic acid or folinic acid warnings and precautions  due to ca content no more than  ml  mg of levoleucovorin solution should be injected intravenously per minute  fusilev enhances the toxicity of fluorouracil deaths from severe enterocolitis diarrhea and dehydration have been reported in elderly patients receiving weekly dlleucovorin and fluorouracil when these drugs are administered concurrently in the palliative treatment of advanced colorectal cancer the dosage of fu must be lower than usually administered although the toxicities observed in patients treated with the combination of fusilev and fu are qualitatively similar to those observed with fu alone gastrointestinal toxicities particularly stomatitis and diarrhea are observed more commonly and may be of greater severity and of prolonged duration in patients treated with the combination  concomitant use of dlleucovorin with trimethoprimsulfamethoxazole for pneumocystis carinii pneumonia in hiv patients was associated with increased rates of treatment failure in a placebocontrolled study adverse reactions  allergic reactions were reported in patients receiving fusilev  the most common adverse reactions  in patients with advanced colorectal cancer receiving fusilev in combination with fu were diarrhea nausea and stomatitis  vomiting  stomatitis  and nausea  were reported in patients receiving fusilev as rescue after high dose methotrexate therapy drug interactions fusilev may counteract the antiepileptic effect of phenobarbital phenytoin and primidone and increase the frequency of seizures in susceptible patients fusilev adverse event profile adverse reactions ≥  in either arm in patients with advanced metastatic colorectal cancer adverse reactionlevoleucovorinfu ndlleucovorinfu n adverse event n grade –grade –grade –grade – gastrointestinal disorders stomatitis     diarrhea     nausea     vomiting     abdominal pain     general disorders astheniafatiguemalaise     metabolism and nutrition anorexiadecreased appetite     skin disorders dermatitis     alopecia      includes abdominal pain upper abdominal pain lower abdominal pain and abdominal tenderness please see the fusilev levoleucovorin for injection full prescribing information for complete safety information isi   indications and usage for folotyn folotyn is indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma the indication for folotyn is based on overall response rate clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated folotyn was the first chemotherapy approved by the us food  drug administration fda for the treatment of relapsed or refractory ptcl please find information about folotyn on this website including efficacy safety dosing  administration side effect management and the allos patient support program asap important safety information for folotyn warnings and precautions  folotyn may suppress bone marrow function manifested by thrombocytopenia neutropenia and anemia monitor blood counts and omit andor reduce dose for hematologic toxicities  mucositis may occur monitor at least weekly if ≥grade  mucositis is observed omit andor reduce dose patients should be instructed to take folic acid and receive vitamin b to potentially reduce treatmentrelated hematological toxicity and mucositis  dermatologic reactions including fatal reactions have occurred and may be progressive and increase in severity with further treatment patients with dermatologic reactions should be monitored closely and omit andor reduce dose or discontinue folotyn  tumor lysis syndrome may occur monitor patients and treat promptly  folotyn can cause hepatic toxicity and liver function test abnormalities monitor liver function tests and if abnormalities are ≥grade  omit until recovery then reduce dose or discontinue folotyn as required  patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity monitor patients for renal function and systemic toxicity and adjust dosing accordingly avoid folotyn use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk  folotyn can cause fetal harm women should avoid becoming pregnant while being treated with folotyn and pregnant women should be informed of the potential harm to the fetus adverse reactions  the most common adverse reactions were mucositis  thrombocytopenia  nausea  and fatigue  the most common serious adverse events were pyrexia mucositis sepsis febrile neutropenia dehydration dyspnea and thrombocytopenia drug interactions  coadministration with probenecid or other drugs that may affect relevant transporter systems eg nsaids requires close monitoring for signs of systemic toxicity use in specific populations  nursing mothers should be advised to discontinue nursing or the drug taking into consideration the importance of the drug to the mother  the folotyn dose is reduced for patients with severe renal impairment egfr  to   mlmin m for patients with mild to moderate renal impairment dose reduction is not necessary please see folotyn full prescribing information indications and usage for zevalin zevalin is a cddirected radiotherapeutic antibody administered as part of the zevalin therapeutic regimen indicated for the treatment of patients with relapsed or refractory lowgrade or follicular bcell nonhodgkins lymphoma nhl previously untreated follicular nhl who achieve a partial or complete response to firstline chemotherapy important safety information for zevalin warning serious infusion reactions prolonged and severe cytopenias and severe cutaneous and mucocutaneous reactions serious infusion reactions deaths have occurred within  hours of rituximab infusion an essential component of the zevalin therapeutic regimen these fatalities were associated with hypoxia pulmonary infiltrates acute respiratory distress syndrome myocardial infarction ventricular fibrillation or cardiogenic shock most  fatalities occurred with the first rituximab infusion discontinue rituximab and y zevalin infusions in patients who develop severe infusion reactions prolonged and severe cytopenias y zevalin administration results in severe and prolonged cytopenias in most patients do not administer y zevalin to patients with ≥ lymphoma marrow involvement andor impaired bone marrow reserve severe cutaneous and mucocutaneous reactions severe cutaneous and mucocutaneous reactions some fatal can occur with the zevalin therapeutic regimen discontinue rituximab and y zevalin infusions in patients experiencing severe cutaneous or mucocutaneous reactions dosing the dose of y zevalin should not exceed  mci  mbq risk of developing myelodysplastic syndrome leukemia and other malignancies the radiation dose resulting from therapeutic exposure to y radiolabeled zevalin may result in secondary malignancies myelodysplastic syndrome mds andor acute myelogenous leukemia aml were reported in   of patients with relapsed or refractory nhl enrolled in clinical studies and   of patients included in the expandedaccess trial with median followup of  and  years respectively among the  reported cases the median time to diagnosis of mds or aml was  years following treatment with the zevalin therapeutic regimen however the cumulative incidence continues to increase among  patients receiving yzevalin following firstline chemotherapy   patients in the zevalin arm developed a second primary malignancy compared to   of patients in the control arm seven patients   were diagnosed with mdsaml after receiving zevalin compared to one patient   in the control arm with a median followup of  years deaths due to second primary malignancy included   patients in the zevalin arm compared to   patients in the control arm deaths due to mdsaml included five  patients in the zevalin arm compared to no patients in the control arm extravasation monitor for extravasation and terminate infusion if it occurs resume infusion in another limb immunization do not administer live viral vaccines to patients who recently received zevalin radionuclide precautions during and after radiolabeling zevalin with y minimize radiation exposure to patients and to medical personnel consistent with institutional good radiation safety practices and patient management procedures embryofetal toxicity may cause fetal harm if given during pregnancy impairment of fertility there is a potential risk that the zevalin therapeutic regimen could cause toxic effects on the male and female gonads effective contraceptive methods should be used during treatment and for up to  months following the zevalin therapeutic regimen nursing mothers patients should be advised to discontinue nursing during and after zevalin treatment adverse reactions the most common adverse reactions of zevalin are cytopenias fatigue nasopharyngitis nausea abdominal pain asthenia cough diarrhea and pyrexia common adverse reactions ≥ in clinical trials were cytopenias fatigue nasopharyngitis nausea abdominal pain asthenia cough diarrhea and pyrexia the most serious adverse reactions of zevalin are prolonged and severe cytopenias thrombocytopenia anemia lymphopenia neutropenia and secondary malignancies when administered following firstline chemotherapy grade  adverse reactions of zevalin include prolonged and severe cytopenias thrombocytopenia  neutropenia  leukopenia  lymphopenia  and anemia  and secondary malignancies  cytopenias were more severe and more prolonged among eleven  patients who received zevalin after firstline fludarabine or a fludarabinecontaining chemotherapy regimen as compared to patients receiving nonfludarabinecontaining regimens grade  infections occurred in  of zevalintreated patients and in  of controls and included neutropenic sepsis  bronchitis catheter sepsis diverticulitis herpes zoster influenza lower respiratory tract infection sinusitis and upper respiratory tract infection grade  adverse reactions of zevalin in relapsed or refractory nhl patients include prolonged and severe cytopenias thrombocytopenia  neutropenia  anemia  and ecchymosis   and secondary malignancies  serious infections occurred in  of patients urinary tract infection febrile neutropenia sepsis pneumonia cellulitis colitis diarrhea osteomyelitis and upper respiratory tract infection lifethreatening infections were reported in  of patients sepsis empyema pneumonia febrile neutropenia fever and biliary stentassociated cholangitis please click here to see the full prescribing information including boxed warnings for zevalin because the zevalin therapeutic regimen includes the use of rituximab please also consult prescribing information for rituximab wwwrituxancom isi indications and usage for marqibomarqibo is indicated for the treatment of adult patients with philadelphia chromosomenegative ph acute lymphoblastic leukemia all in second or greater relapse or whose disease has progressed following  or more antileukemia therapies this indication is based on overall response rate clinical benefit such as improvement in overall survival has not been verified important safety information for marqibo warning for intravenous use onlyfatal if given by other routes death has occurred with intrathecal administration marqibo vincristine sulfate liposome injection has different dosage recommendations than vincristine sulfate injection verify drug name and dose prior to preparation and administration to avoid overdosage contraindications  marqibo is contraindicated in patients with demyelinating conditions including charcotmarietooth syndrome in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo and for intrathecal administration warnings and precautions  marqibo is for intravenous use onlyfatal if given by other routes intrathecal use is fatal  extravasation causes tissue injury if extravasation is suspected discontinue infusion immediately and consider local treatment measures  sensory and motor neuropathy are common and cumulative monitor patients for peripheral motor and sensory central and autonomic neuropathy and reduce interrupt or discontinue dosing patients with preexisting severe neuropathy should be treated with marqibo only after careful riskbenefit assessment  neutropenia thrombocytopenia or anemia may occur monitor blood counts prior to each dose consider dose modification or reduction as well as supportive care measures if grade  or  myelosuppression develops  anticipate monitor for and manage tumor lysis syndrome  a prophylactic bowel regimen should be instituted with marqibo to prevent constipation bowel obstruction andor paralytic ileus  severe fatigue can occur requiring dose delay reduction or discontinuation of marqibo  fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred monitor liver function and modify or interrupt dosing for hepatic toxicity  marqibo can cause fetal harm advise women of potential risk to fetus adverse events  the most commonly reported adverse reactions incidence  in clinical studies include constipation  nausea  pyrexia  fatigue  peripheral neuropathy  febrile neutropenia  diarrhea  anemia  decreased appetite  and insomnia   a total of  of patients experienced serious adverse events saes during the studies the most commonly reported saes included febrile neutropenia  pyrexia  hypotension  respiratory distress  and cardiac arrest   twentyeight percent of patients experienced adverse reactions leading to treatment discontinuation the most common adverse reactions that caused treatment discontinuation were peripheral neuropathy  leukemiarelated  and tumor lysis syndrome   deaths occurred in  of patients in study  the nonleukemiarelated causes of death were brain infarct  intracerebral hemorrhage  liver failure  multisystem organ failure  pneumonia and septic shock  respiratory failure  pulmonary hemorrhage  and sudden cardiac death  drug interactions  marqibo is expected to interact with drugs known to interact with nonliposomal vincristine sulfate therefore the concomitant use of strong cypa inhibitors or the use of potent pglycoprotein inhibitors or inducers should be avoided use in specific populations  the safety and effectiveness of marqibo in pediatric patients have not been established  it is not known whether marqibo is excreted in human milk please click here to see the full prescribing information including boxed warnings for marqibo isi indications and usage for beleodaqbeleodaq is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral tcell lymphoma ptcl this indication is approved under accelerated approval based on tumor response rate and duration of response an improvement in survival or diseaserelated symptoms has not been established continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial important safety information for beleodaq warnings and precautions beleodaq can cause thrombrocytopenia leukopenia neutropenia and lymphopenia andor anemia monitor blood counts weekly during treatment and modify dosage as necessary serious and sometimes fatal infections including pneumonia and sepsis have occurred with beleodaq do not administer beleodaq to patients with an active infection patients with a history of extensive or intensive chemotherapy may be at higher risk of life threatening infections beleodaq can cause fatal hepatotoxicity and liver function test abnormalities monitor liver function tests before treatment and before the start of each cycle interrupt or adjust dosage until recovery or permanently discontinue beleodaq based on the severity of the hepatic toxicity tumor lysis syndrome has occurred in beleodaqtreated patients in the clinical trial of patients with relapsed or refractory ptcl monitor patients with advanced stage disease andor high tumor burden and take appropriate precautions nausea vomiting and diarrhea occur with beleodaq and may require the use of antiemetic and antidiarrheal medications beleodaq can cause fetal harm when administered to a pregnant woman women of childbearing potential should be advised to avoid pregnancy while receiving beleodaq if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of potential hazard to the fetus adverse reactions the most common adverse reactions observed in the trial in patients with relapsed or refractory ptcl treated with beleodaq were nausea  fatigue  pyrexia  anemia  and vomiting  sixtyone patients  experienced serious adverse reactions while taking beleodaq or within  days after their last dose of beleodaq drug interactions beleodaq is primarily metabolized by ugta avoid concomitant administration of beleodaq with strong inhibitors of ugta use in specific populations it is not known whether belinostat is excreted in human milk because of the potential for serious adverse reactions in nursing infants from beleodaq a decision should be made whether to discontinue nursing or discontinue drug taking into account the importance of the drug to the mother please click here to see beleodaq full prescribing information isi indications and usage for evomela evomela is an alkylating drug indicated for use as a highdose conditioning treatment prior to hematopoietic progenitor stem cell transplantation in patients with multiple myeloma the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate important safety information for evomela warning severe bone marrow suppression hypersensitivity and leukemogenicity severe bone marrow suppression with resulting infection or bleeding may occur controlled trials comparing intravenous iv melphalan to oral melphalan have shown more myelosuppression with the iv formulation monitor hematologic laboratory parameters hypersensitivity reactions including anaphylaxis have occurred in approximately  of patients who received the iv formulation of melphalan discontinue treatment with evomela for serious hypersensitivity reactions melphalan produces chromosomal aberrations in vitro and in vivo evomela should be considered potentially leukemogenic in humans contraindications history of serious allergic reaction to melphalan warnings and precautions bone marrow suppression for patients receiving evomela as part of a conditioning regimen myeloablation occurs in all patients do not begin the conditioning regimen if a stem cell product is not available for rescue monitor complete blood counts provide supportive care for infections anemia and thrombocytopenia until there is adequate hematopoietic recovery for patients receiving evomela as palliative treatment if the bone marrow has been compromised by prior irradiation prior chemotherapy or is recovering from chemotherapy the risk of severe myelosuppression with evomela is increased perform periodic complete blood counts during the course of treatment with evomela provide supportive care for infections bleeding and symptomatic anemia gastrointestinal toxicity for patients receiving evomela as part of a conditioning regimen nausea vomiting mucositis and diarrhea may occur in over  of patients use prophylactic antiemetic medication provide supportive care for nausea vomiting diarrhea and mucositis the frequency of grade  mucositis in clinical studies was  provide nutritional support and analgesics for patients with severe mucositis for patients receiving evomela as palliative treatment nausea and vomiting diarrhea and oral ulceration may occur use prophylactic antiemetics provide supportive care for nausea vomiting diarrhea and mucositis hepatotoxicity hepatic disorders ranging from abnormal liver function tests to clinical manifestations such as hepatitis and jaundice have been reported after treatment with melphalan hepatic venoocclusive disease has also been reported monitor liver chemistries hypersensitivity acute hypersensitivity reactions including anaphylaxis have occurred in approximately  of patients who received an intravenous formulation of melphalan symptoms may include urticaria pruritus edema and skin rashes and in some patients tachycardia bronchospasm dyspnea and hypotension discontinue treatment with evomela for serious hypersensitivity reactions secondary malignancies secondary malignancies such as myeloproliferative syndrome or acute leukemia have been reported in multiple myeloma patients treated with melphalancontaining chemotherapy regimens the potential benefit of evomela therapy must be considered against the possible risk of the induction of a secondary malignancy embryofetal toxicity evomela can cause fetal harm when administered to a pregnant woman advise females of reproductive potential to avoid pregnancy during and after treatment with evomela if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug advise the patient of potential risk to the fetus infertility melphalanbased chemotherapy regimens have been reported to cause suppression of ovarian function in premenopausal women resulting in persistent amenorrhea in approximately  of patients reversible or irreversible testicular suppression has also been reported adverse events the most common adverse reactions observed in at least  of patients with multiple myeloma treated with evomela were neutrophil count decreased  white blood cell count decreased  lymphocyte count decreased  platelet count decreased  diarrhea  nausea  fatigue  hypokalemia  anemia  and vomiting  for myeloablative conditioning in multiple myeloma patients undergoing asct twelve  patients experienced a treatment emergent serious adverse reaction while on study the most common serious adverse reactions  patient  were pyrexia hematochezia febrile neutropenia and renal failure treatmentrelated serious adverse reactions reported in  patient were pyrexia n  febrile neutropenia n  and hematochezia n  in a randomized clinical trial studying the palliative treatment of patients with multiple myeloma severe myelotoxicity wbc ≤ andor platelets ≤ was more common in the iv melphalan arm  than in the oral melphalan arm  in this randomized study the rate of severe leukopenia in the iv arm in the patients with bun over  mgdl decreased from   to   after  reduction in iv melphalan dose in addition the incidence of drugrelated death in the iv arm decreased from   to   after this dose reduction this compares to an overall   incidence of drugrelated death in the oral melphalan arm drug interactions no formal drug interaction studies have been conducted when nalidixic acid and iv melphalan are given simultaneously the incidence of severe hemorrhagic necrotic enterocolitis has been reported to increase in pediatric patients use in specific populations lactation it is not known whether melphalan is present in human milk because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from melphalan breastfeeding is not recommended during treatment with evomela patients with renal impairment for palliative treatment consider dose reduction for patients with renal impairment receiving evomela bone marrow suppression has been observed in patients with bun levels ≥ mgdl a  reduction in the iv melphalan dose decreased the incidence of severe bone marrow suppression in the latter portion of this study please click here to see full prescribing information including boxed warnings for evomela isippevo back to top our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient information medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policycontact us  webmail sppi insider trading  spectrum pharmaceuticals inc  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  spectrum pharmaceuticals inc sppi select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in goto page   next common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm casi pharmaceuticals inc casi spectrum pharmaceuticals incspectrum pharmaceuticals cayman lp owner    directindirect view purchase  pm casi pharmaceuticals inc casi spectrum pharmaceuticals incspectrum pharmaceuticals cayman lp owner    directindirect view purchase  pm casi pharmaceuticals inc casi spectrum pharmaceuticals incspectrum pharmaceuticals cayman lp owner    directindirect view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view option award  pm na spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view option award  pm na spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view option award  pm na spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view option award  pm na spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view option award  pm na spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view option award  pm nana spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   direct view option award  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view option award  pm nana spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view exercise  pm nana spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   indirect view tax withholding  pm nana spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   indirect view exercise  pm nana spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   indirect view tax withholding  pm nana spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   indirect view exercise  pm  spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   indirect view exercise  pm  spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   indirect view option award  pm na spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view option award  pm na spectrum pharmaceuticals inc sppi shrotriya rajesh c mdchairman  ceodirector owner   direct view option award  pm na spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view exercise  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view exercise  pm na spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view option award  pm na spectrum pharmaceuticals inc sppi maida anthony e iiidirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view option award  pm na spectrum pharmaceuticals inc sppi lenaz luigi mddirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view option award  pm na spectrum pharmaceuticals inc sppi krassner stuart mitchelldirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi gagnon gillesdirector   direct view option award  pm na spectrum pharmaceuticals inc sppi gagnon gillesdirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view option award  pm na spectrum pharmaceuticals inc sppi cohen raymond wdirector   direct view option award  pm nana spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view option award  pm na spectrum pharmaceuticals inc sppi vyas dolatraidirector   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi gustafson kurt aevp  chief financial officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi allen lee f md phdchief medical officer   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi turgeon joseph wpresident  coo   direct view tax withholding  pm nana spectrum pharmaceuticals inc sppi allen lee f md phdchief medical officer   direct view goto page   next   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  spectrum pharmaceuticals cayman lp board committees  members  bloomberg july    pm et company overview of spectrum pharmaceuticals cayman lp snapshotpeople  overviewboard memberscommittees there is no committee data available data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most active committee members by competitorsymbolcommittee membernumber of committeesthere is no active committee members data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact spectrum pharmaceuticals cayman lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close license and asset purchase agreement dated as of november   between spectrum pharmaceuticals cayman lp and mundipharma international corporation limited limitation of liability clause  asset purchase agreement agreement  new york  spectrum pharmaceuticals inc  you are here contract clause  asset purchase agreement clauses    limitation of liability search documents  browse documents site search agreements  contracts document title entire documentoptional governing lawoptional allalabamaalaskaarizonaarkansascaliforniacoloradoconnecticutdelawareflorida georgiahawaiiidahoillinoisindianaiowakansaskentuckylouisianamainemaryland massachusettsmichiganminnesotamississippimissourimontananebraskanevada new hampshirenew jerseynew mexiconew yorknorth carolinanorth dakotaohiooklahoma oregonpennsylvaniarhode islandsouth carolinasouth dakotatennesseetexasutah vermontvirginiawashingtonwest virginiawisconsinwyoming try our advanced search  clauses search contract clauses  browse contract clause library you are currently viewing this asset purchase agreement limitation of liability clause is from the contract involving spectrum pharmaceuticals inc  mundipharma international corporation limited  spectrum pharmaceuticals cayman lp  spectrum pharmaceuticals international holdings llc  spectrum pharmaceuticals inc realdealdocs contains millions of easily searchable legal documents and clauses from top law firms search our legal agreements or our contract clause library for free title license and asset purchase agreement dated as of november   between spectrum pharmaceuticals cayman lp and mundipharma international corporation limited governing law license agreement new york date  industry biotechnology and drugs     law firm chadbourne parke     sector healthcare  of the top  law firms use our products every day   limitation of liability no party shall be liable to any other party for any claims for consequential incidental punitive business interruption exemplary or indirect damages or lost profits arising under statute in tort contract or otherwise the foregoing limitation will not apply to limit any partys liability with respect to a a third party claim b fraud or c criminal acts spectrum pharmaceuticals nasdaqsppi home search signinup contracts dictionary clauses companies people about faq blog spectrum pharmaceuticals executives officer evp  chief financial officer kurt gustafson director rajesh c shrotriya director luigi lenaz director stuart m krassner officer chief commercial officer joseph turgeon officer cso and head of rd operations george tidmarsh officer chief medical officer lee allen officer vpfinance strategic planning john l mcmanus officer evp  chief operating officer joseph keller officer acting chief financial officer brett scott officer chief commercial officer jim shields director dr dilip mehta officer sr vice president finance shyam kumaria director richard fulmer director dr paul silverman related companies dimensional pharmaceutical sbio inc adr health ap pharma inc ac immune sa acadia pharmaceuticals adventrx pharmaceuticals inc alda pharmaceuticals corp ani pharmaceuticals inc avi biopharma inc abbvie abbott laboratories abraxis bioscience abraxis bioscience acambis more related companies home sample contracts by company spectrum pharmaceuticals spectrum pharmaceuticals loading former names neotherapeutics inc until stock nasdaqsppistandard industryclassification pharmaceutical preparationsaddress  s eastern ave suite  henderson nv  phone official website httpwwwspectrumpharmcommore info wikipedia executives officer evp  chief financial officer kurt gustafson director rajesh c shrotriya director luigi lenaz director stuart m krassner officer chief commercial officer joseph turgeon officer cso and head of rd operations george tidmarsh officer chief medical officer lee allen officer vpfinance strategic planning john l mcmanus officer evp  chief operating officer joseph keller officer acting chief financial officer brett scott officer chief commercial officer jim shields director dr dilip mehta officer sr vice president finance shyam kumaria director richard fulmer director dr paul silverman sample contracts confidential license and asset purchase agreement dated as of january   between spectrum pharmaceuticals cayman lp may th  this license and asset purchase agreement dated as of january   the execution date as amended or otherwise modified the agreement is between spectrum pharmaceuticals cayman lp an exempted limited partnership organized under the laws of the cayman islands purchaser and bayer pharma ag a german aktiengesellschaft bayer spectrum pharmaceuticals inc  incentive award plan performance unit award grant notice may th  spectrum pharmaceuticals inc a delaware corporation the company pursuant to the spectrum pharmaceuticals inc  incentive award plan as amended from time to time the plan hereby grants to the individual listed below the participant in consideration of the mutual agreements set forth herein and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged a performancebased restricted stock unit award the performance units each performance unit represents the right to receive one share of common stock as defined in the plan upon the achievement of total stockholder return goals the shares this award is subject to all of the terms and conditions set forth herein and in the performance unit award agreement attached hereto as exhibit a the performance unit award agreement and the plan each of which are incorporated herein by reference unless otherwise defined herein the terms defined in the plan shall license agreement august th  whereas cydex is engaged in the business of developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and developmentstage drugs license and asset purchase agreement dated as of november   between spectrum pharmaceuticals cayman lp june th  this license and asset purchase agreement dated as november   the effective date as amended or otherwise modified the agreement is between spectrum pharmaceuticals cayman lp an exempted limited partnership organized under the laws of the cayman islands spectrum and mundipharma international corporation limited a bermuda corporation purchaser copromotion agreement march th  this copromotion agreement this agreement is entered into as of november   the effective date by and between eagle pharmaceuticals inc a corporation organized under the laws of delaware with offices at  tice blvd suite  woodcliff lake nj  eagle and spectrum pharmaceuticals inc a corporation organized under the laws of delaware with offices at  south eastern avenue suite  henderson nevada  spectrum each of eagle and spectrum is sometimes referred to individually herein as a party and collectively as the parties license and asset purchase agreement dated as of november   between spectrum pharmaceuticals cayman lp march th  this license and asset purchase agreement dated as november   the effective date as amended or otherwise modified the agreement is between spectrum pharmaceuticals cayman lp an exempted limited partnership organized under the laws of the cayman islands spectrum and mundipharma international corporation limited a bermuda corporation purchaser supply agreement march th  this supply agreement this agreement dated this th day of november  the effective date is by and between spectrum pharmaceuticals cayman lp an exempted limited partnership organized under the laws of the cayman islands spectrum and mundipharma medical company a partnership organized under the laws of bermuda having a place of business at  parlaville road po box hm  hamilton hm jx bermuda mmco indenture december rd  indenture dated as of    between spectrum pharmaceuticals inc a delaware corporation company and name of trustee a  trustee spectrum pharmaceuticals inc amendment no  to  incentive award plan november th  this amendment no  to the  incentive award plan the plan of spectrum pharmaceuticals inc a delaware corporation the company is made effective as of april   capitalized terms used herein but otherwise not defined shall have the meanings set forth in the plan spectrum pharmaceuticals inc amendment no  to  amended and restated incentive award plan november th  this amendment no  to the  amended and restated incentive award plan the plan of spectrum pharmaceuticals inc a delaware corporation the company is made effective as of april   capitalized terms used herein but otherwise not defined shall have the meanings set forth in the plan first amendment to amended and restated license development and commercialization agreement august th  this first amendment amendment is entered into as of may   and effective as of may   the amendment effective date by and between allos therapeutics inc a delaware corporation the allos and mundipharma international corporation limited a bermuda corporation mundipharma change in control severance agreement august th  this amendment no  to change in control severance agreement the amendment is entered into as of august   by and between spectrum pharmaceuticals inc a delaware corporation the company which term shall include any successor by merger consolidation sale of substantially all of the companys assets or otherwise and joseph w turgeon employee all capitalized terms that have not been defined herein shall have the meanings ascribed to such terms in the change in control severance agreement dated march   as amended february   the agreement by and between the company and employee investment agreement september th  this investment agreement this investment agreement is made as of september   by and between casi pharmaceuticals inc a delaware corporation the company and spectrum pharmaceuticals inc a delaware corporation the investor investment agreement september th  this investment agreement this investment agreement is made as of september   by and between casi pharmaceuticals inc a delaware corporation the company and spectrum pharmaceuticals cayman lp an exempted limited partnership organized under the laws of the cayman islands the investor lease agreement august th  tenants permitted use general office and other legally permitted uses compatible with office buildings of comparable quality to the building but only to the extent permitted by the city in which the leased premises are located and all agencies and governmental authorities having jurisdiction of the leased premises first amendment to executive employment agreement august th  this first amendment to executive employment agreement this amendment is dated effective as of april    the effective date between spectrum pharmaceuticals inc a delaware corporation corporation and dr rajesh c shrotriya executive first amendment to license agreement june th  this first amendment amendment is entered into as of june   and effective as of january   the amendment effective date by and between spectrum pharmaceuticals inc a delaware corporation hereinafter referred to as spectrum and merck eprova ag a swiss corporation hereinafter referred to as epro and amends the license agreement by and between spectrum and epro dated as of may   the license agreement as follows change in control severance agreement march st  change in control severance agreement this agreement dated as of march   by and between spectrum pharmaceuticals inc the company and the employee spectrum pharmaceuticals inc as issuer  convertible senior notes due  indenture dated as of december   wilmington trust national association as trustee december rd  indenture dated as of december   between spectrum pharmaceuticals inc a delaware corporation as issuer company as more fully set forth in section  and wilmington trust national association as trustee trustee as more fully set forth in section  spectrumpharmaceuticals inc december rd  the purpose of this letter agreement this confirmation is to confirm the terms and conditions of the warrants issued by spectrum pharmaceuticals inc company to royal bank of canada dealer as of the trade date specified below the transaction this letter agreement constitutes a confirmation as referred to in the isda master agreement specified below spectrumpharmaceuticals inc december rd  the purpose of this letter agreement this confirmation is to confirm the terms and conditions of the call option transaction entered into between royal bank of canada dealer and spectrum pharmaceuticals inc counterparty as of the trade date specified below the transaction this letter agreement constitutes a confirmation as referred to in the isda master agreement specified below spectrumpharmaceuticals inc december rd  the purpose of this letter agreement this confirmation is to confirm the terms and conditions of the call option transaction entered into between royal bank of canada dealer and spectrum pharmaceuticals inc counterparty as of the trade date specified below the transaction this letter agreement constitutes a confirmation as referred to in the isda master agreement specified below spectrum pharmaceuticals inc  convertible senior notes due  purchase agreement december rd  spectrumpharmaceuticals inc december rd  the purpose of this letter agreement this confirmation is to confirm the terms and conditions of the warrants issued by spectrum pharmaceuticals inc company to royal bank of canada dealer as of the trade date specified below the transaction this letter agreement constitutes a confirmation as referred to in the isda master agreement specified below amendment to license and collaboration agreement november th  this amendment this amendment effective as of october   the amendment date is made by and between topotarget as a danish corporation having its principal offices at symbion science park fruebjergvej   kobenhavn denmark topotarget and spectrum pharmaceuticals inc a delaware corporation having a place of business at  s eastern avenue suite  henderson nevada  usa spectrum and amends the license and collaboration agreement dated february   by and between spectrum and topotarget the license agreement topotarget and spectrum are sometimes referred to herein individually as a party and collectively as the parties any capitalized terms used but not defined herein will have the meaning ascribed to such terms in the license agreement amendment to license and collaboration agreement october th  this amendment this amendment effective as of october   the amendment date is made by and between topotarget as a danish corporation having its principal offices at symbion science park fruebjergvej   kobenhavn denmark topotarget and spectrum pharmaceuticals inc a delaware corporation having a place of business at  s eastern avenue suite  henderson nevada  usa spectrum and amends the license and collaboration agreement dated february   by and between spectrum and topotarget the license agreement topotarget and spectrum are sometimes referred to herein individually as a party and collectively as the parties any capitalized terms used but not defined herein will have the meaning ascribed to such terms in the license agreement contract august th  contract august th  amendment no  to credit agreement july th  this amendment no  to credit agreement the amendment dated as of july   is made by and among spectrum pharmaceuticals inc a delaware corporation the borrower allos therapeutics inc a delaware corporation the other loan parties as defined in the credit agreement as defined below signatory hereto bank of america na in its capacity as administrative agent for the lenders as defined in the credit agreement in such capacity the administrative agent and as swingline lender and lc issuer and each of the lenders signatory hereto each capitalized term used and not otherwise defined in this amendment has the definition specified in the credit agreement stock purchase agreement july th  this stock purchase agreement this agreement is made as of july   by and among spectrum pharmaceuticals inc a delaware corporation parent talon therapeutics inc a delaware corporation the company and eagle acquisition merger sub inc a delaware corporation purchaser securities purchase agreement by and among spectrum pharmaceuticals inc eagle acquisition merger sub inc and the securityholders of talon therapeutics inc named herein july   july th  this securities purchase agreement this agreement is made and entered into as of july   by and among spectrum pharmaceuticals inc a delaware corporation parent eagle acquisition sub inc a delaware corporation purchaser warburg pincus private equity x lp wpx warburg pincus x partners lp wppx and together with wpx the wp entities deerfield private design fund lp deerfield private design fund deerfield special situations fund lp deerfield special situations fund deerfield special situations fund international limited deerfield international and deerfield private design international lp deerfield private design international and together with deerfield private design fund deerfield special situation fund and deerfield international the deerfield entities the wp entities and the deerfield entities shall be referred to herein individually as seller and collectively as sellers contingent value rights agreement july th  this contingent value rights agreement dated as of july   this agreement is entered into by and among spectrum pharmaceuticals inc a delaware corporation parent talon therapeutics inc a delaware corporation the company and corporate stock transfer inc as rights agent the rights agent exchange agreement july th  this exchange agreement this agreement dated as of july   is by and among spectrum pharmaceuticals inc a delaware corporation spectrum talon therapeutics inc a delaware corporation talon deerfield private design fund lp deerfield private design fund deerfield special situations fund lp a limited partnership organized under the laws of delaware deerfield special situations fund deerfield special situations fund international limited a company organized under the laws of the british virgin islands deerfield international and deerfield private design international lp a limited partnership organized under the laws of the british virgin islands deerfield private design international and together with deerfield private design fund deerfield special situations fund and deerfield international the lenders license agreement may th  whereas cydex is engaged in the business of developing and commercializing novel drug delivery technologies designed to enhance the solubility and effectiveness of existing and developmentstage drugs supply agreement may th  whereas cydex and spectrum are also parties to that certain license agreement of even date herewith the license agreement and × have an account sign in here law insider recover your password no account register now no account register now sign in by using one of this services or forgot your password have an account sign in here join law insider for free by using one of this services or by registering you agree to our terms of service spectrum pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports spectrum pharmaceuticals inc  product pipeline review  spectrum pharmaceuticals inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports spectrum pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘spectrum pharmaceuticals inc  product pipeline review  ’ provides an overview of the spectrum pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of spectrum pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of spectrum pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of spectrum pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the spectrum pharmaceuticals inc’s pipeline productsreasons to buy evaluate spectrum pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of spectrum pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the spectrum pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of spectrum pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of spectrum pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of spectrum pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures spectrum pharmaceuticals inc snapshot spectrum pharmaceuticals inc overview key information key facts spectrum pharmaceuticals inc  research and development overview key therapeutic areas spectrum pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities spectrum pharmaceuticals inc  pipeline products glance spectrum pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities spectrum pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities spectrum pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities spectrum pharmaceuticals inc  drug profiles belinostat product description mechanism of action rd progress apaziquone product description mechanism of action rd progress ibritumomab tiuxetan product description mechanism of action rd progress pralatrexate product description mechanism of action rd progress vincristine sulfate liposomal product description mechanism of action rd progress lucanthone hydrochloride product description mechanism of action rd progress melphalan product description mechanism of action rd progress menadione product description mechanism of action rd progress ortataxel product description mechanism of action rd progress ozarelix product description mechanism of action rd progress spi product description mechanism of action rd progress spi product description mechanism of action rd progress leteprinim potassium lipid suspension product description mechanism of action rd progress mtrn product description mechanism of action rd progress topotecan hydrochloride liposomal product description mechanism of action rd progress vinorelbine tartrate liposomal product description mechanism of action rd progress rituximab biosimilar product description mechanism of action rd progress spectrum pharmaceuticals inc  pipeline analysis spectrum pharmaceuticals inc  pipeline products by target spectrum pharmaceuticals inc  pipeline products by route of administration spectrum pharmaceuticals inc  pipeline products by molecule type spectrum pharmaceuticals inc  pipeline products by mechanism of action spectrum pharmaceuticals inc  recent pipeline updates spectrum pharmaceuticals inc  dormant projects spectrum pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles efaproxiral ortataxel ozarelix rh spectrum pharmaceuticals inc  company statement spectrum pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesspectrum pharmaceuticals inc key information spectrum pharmaceuticals inc key facts spectrum pharmaceuticals inc  pipeline by indication  spectrum pharmaceuticals inc  pipeline by stage of development  spectrum pharmaceuticals inc  monotherapy products in pipeline  spectrum pharmaceuticals inc  partnered products in pipeline  spectrum pharmaceuticals inc  partnered products combination treatment modalities  spectrum pharmaceuticals inc  preregistration  spectrum pharmaceuticals inc  phase iii  spectrum pharmaceuticals inc  phase ii  spectrum pharmaceuticals inc  phase i  spectrum pharmaceuticals inc  preclinical  spectrum pharmaceuticals inc  pipeline by target  spectrum pharmaceuticals inc  pipeline by route of administration  spectrum pharmaceuticals inc  pipeline by molecule type  spectrum pharmaceuticals inc  pipeline products by mechanism of action  spectrum pharmaceuticals inc  recent pipeline updates  spectrum pharmaceuticals inc  dormant developmental projects spectrum pharmaceuticals inc  discontinued pipeline products  spectrum pharmaceuticals inc other locations spectrum pharmaceuticals inc subsidiaries list of figuresspectrum pharmaceuticals inc  pipeline by top  indication  spectrum pharmaceuticals inc  pipeline by stage of development  spectrum pharmaceuticals inc  monotherapy products in pipeline  spectrum pharmaceuticals inc  partnered products in pipeline  spectrum pharmaceuticals inc  pipeline by top  target  spectrum pharmaceuticals inc  pipeline by top  route of administration  spectrum pharmaceuticals inc  pipeline by top  molecule type  spectrum pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send spectrum pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals spectrum pharmaceuticals inc  product pipeline review   published apr  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample spectrum pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘spectrum pharmaceuticals inc  product pipeline review  ’ provides an overview of the spectrum pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of spectrum pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of spectrum pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of spectrum pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the spectrum pharmaceuticals inc’s pipeline products reasons to buy  evaluate spectrum pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of spectrum pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the spectrum pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of spectrum pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of spectrum pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of spectrum pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  spectrum pharmaceuticals inc snapshot  spectrum pharmaceuticals inc overview  key information  key facts  spectrum pharmaceuticals inc  research and development overview  key therapeutic areas  spectrum pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  spectrum pharmaceuticals inc  pipeline products glance  spectrum pharmaceuticals inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  spectrum pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  spectrum pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  spectrum pharmaceuticals inc  unknown stage pipeline products  unknown productscombination treatment modalities  spectrum pharmaceuticals inc  drug profiles  melphalan  product description  mechanism of action  rd progress  apaziquone  product description  mechanism of action  rd progress  pralatrexate  product description  mechanism of action  rd progress  vincristine sulfate  product description  mechanism of action  rd progress  yttritum  ibritumomab tiuxetan  product description  mechanism of action  rd progress  belinostat  product description  mechanism of action  rd progress  lucanthone hydrochloride  product description  mechanism of action  rd progress  menadione  product description  mechanism of action  rd progress  ortataxel  product description  mechanism of action  rd progress  ozarelix  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  mtrn  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  topotecan hydrochloride liposomal  product description  mechanism of action  rd progress  vinorelbine tartrate liposomal  product description  mechanism of action  rd progress  rituximab biosimilar  product description  mechanism of action  rd progress  spectrum pharmaceuticals inc  pipeline analysis  spectrum pharmaceuticals inc  pipeline products by target  spectrum pharmaceuticals inc  pipeline products by route of administration  spectrum pharmaceuticals inc  pipeline products by molecule type  spectrum pharmaceuticals inc  pipeline products by mechanism of action  spectrum pharmaceuticals inc  recent pipeline updates  spectrum pharmaceuticals inc  dormant projects  spectrum pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  efaproxiral  ortataxel  rh  spectrum pharmaceuticals inc  company statement  spectrum pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables spectrum pharmaceuticals inc key information  spectrum pharmaceuticals inc key facts  spectrum pharmaceuticals inc  pipeline by indication   spectrum pharmaceuticals inc  pipeline by stage of development   spectrum pharmaceuticals inc  monotherapy products in pipeline   spectrum pharmaceuticals inc  partnered products in pipeline   spectrum pharmaceuticals inc  partnered products combination treatment modalities   spectrum pharmaceuticals inc  preregistration   spectrum pharmaceuticals inc  phase iii   spectrum pharmaceuticals inc  phase ii   spectrum pharmaceuticals inc  phase i   spectrum pharmaceuticals inc  preclinical   spectrum pharmaceuticals inc  unknown   spectrum pharmaceuticals inc  pipeline by target   spectrum pharmaceuticals inc  pipeline by route of administration   spectrum pharmaceuticals inc  pipeline by molecule type   spectrum pharmaceuticals inc  pipeline products by mechanism of action   spectrum pharmaceuticals inc  recent pipeline updates   spectrum pharmaceuticals inc  dormant developmental projects  spectrum pharmaceuticals inc  discontinued pipeline products   spectrum pharmaceuticals inc other locations  spectrum pharmaceuticals inc subsidiaries  list of figures spectrum pharmaceuticals inc  pipeline by top  indication   spectrum pharmaceuticals inc  pipeline by stage of development   spectrum pharmaceuticals inc  monotherapy products in pipeline   spectrum pharmaceuticals inc  partnered products in pipeline   spectrum pharmaceuticals inc  pipeline by top  target   spectrum pharmaceuticals inc  pipeline by top  route of administration   spectrum pharmaceuticals inc  pipeline by top  molecule type   spectrum pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and europe bcg vaccine market  analysis and outlook to  jul  eu research  pages    code  mrs   this report presents a comprehensive overview of the bcg vaccine market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bcg vaccine industry this report focus global and europe market it covers details playe read more global onychomycosis tinea unguium drug detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in onychomycosis tinea unguium drug industry this report fo read more life science analytics  global market outlook  jun  stratistics mrc  pages    code  mrs   according to stratistics mrc the global life science analytics market is expected to grow from  billion in  to reach  billion by  with a cagr of  some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications increasing need of these solutions especially in clinical trials and improvements in technological advancements however lack of skilled professionals huge implementation costs and financial limitations read more chronic kidney disease ckd drugs  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global chronic kidney disease ckd drugs market is expected to grow from  billion in  to reach  billion by  with a cagr of  drivers that are shaping the global market include growing incidences of chronic kidney diseases rise in aged population rising incidence of diabetes and obesity related disorders significant unmet requirements and beneficial reimbursement policies on the other hand factors such as intense competition fr read more acaricides  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global acaricides market is expected to grow from  million in  to reach  million by  with a cagr of  high demand for meat dairy products and crops growth in crop protection industry and rise in productivity are some of the factors propelling the market growth however increase in cost alternative acaricides sources and regulatory restrictions are the factors suppressing the market on the other hand expansion of bioactive aca read more global and united states bacillus subtilis depth research report  jul  united states research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a depth research report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus united states market it covers details players regions product type and other details as following major companies bayer germany basf germany tonglu huifeng china kernel biotech china w read more global bacterial vaginosis drug market rport  jun  bisreport  pages    code  mrs   global bacterial vaginosis drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the bacterial vaginosis drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years bacterial vaginosis drug market size to maintain read more global alzheimers disease drug market rport  jun  bisreport  pages    code  mrs   global alzheimer’s disease drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the alzheimer’s disease drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years alzheimer’s disease drug market size to maintain read more global protein powder detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in protein powder industry this report splits protein powder market price size first speciality second speciality protein powder flavors which covers the history data information from  to  and forecast from  to  this report focus glob read more opioidinduced constipation oic  pipeline review h  jul  global markets direct  pages    code  mrs   opioidinduced constipation oic  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide opioidinduced constipation oic  pipeline review h  provides an overview of the opioidinduced constipation oic toxicology pipeline landscape opioids are effective pain relievers but often have the side effect of constipation these medicines affect the gastrointestinal tract in a variety of ways opioids increase the amo read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports